World Allergy Organization Journal· 2014Q1
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
- 594citations
- Q1SCImago
- 2014year
Short summary
The World Allergy Organization (WAO) 2013 update to its position paper on sublingual immunotherapy (SLIT) revises and expands upon the 2009 version, incorporating new evidence on mechanisms, clinical efficacy, safety, impact on disease progression, and specific considerations for children.
AI-generated from the title and abstract; the full text is not read.
Key points
- The WAO 2013 update revises and expands the 2009 position paper on sublingual immunotherapy (SLIT).
- New data on clinical efficacy, safety (including a new adverse reaction grading system), and impact on the natural history of respiratory allergy are incorporated.
- Specific chapters address SLIT efficacy in children, patient selection, and practical aspects of dosing and adherence.
- Emerging topics like recombinant allergens, adjuvants, and strategies for raising public awareness are also covered.
AI-generated from the title and abstract; the full text is not read.
Abstract
We have prepared this document, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update", according to the evidence-based criteria, revising and updating chapters of the originally published paper, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2009", available at http://www.waojournal.org. Namely, these comprise: "Mechanisms of sublingual immunotherapy;" "Clinical efficacy of sublingual immunotherapy" - reporting all the data of all controlled trials published after 2009; "Safety of sublingual immunotherapy" - with the recently published Grading System for adverse reactions; "Impact of sublingual immunotherapy on the natural history of respiratory allergy" - with the relevant evidences published since 2009; "Efficacy of SLIT in children" - with detailed analysis of all the studies; "Definition of SLIT patient selection" - reporting the criteria for eligibility to sublingual immunotherapy; "The future of immunotherapy in the community care setting"; "Methodology of clinical trials according to the current scientific and regulatory standards"; and "Guideline development: from evidence-based medicine to patients' views" - including the evolution of the methods to make clinical recommendations.Additionally, we have added new chapters to cover a few emerging crucial topics: "Practical aspects of schedules and dosages and counseling for adherence" - which is crucial in clinical practice for all treatments; "Perspectives and new approaches" - including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single products. Furthermore, "Raising public awareness about sublingual immunotherapy", as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion, are also reported in detail.
The authors' abstract, as published at the source. World Allergy Organization Journal, 2014 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine